Floatz logo

Resminostat

Hepatocellular Carcinoma

Yakult Honsha Co., LTDSmall moleculePhase 2Dormant
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
65/ 100

Competitive context

499 Active assets in the Hepatocellular Carcinoma cohort.

Asset / SponsorPhaseRating
Adefovir
Bukwang Pharmaceutical
Phase 4BBB
Huaier Granule
Tongji Hospital
Phase 4BBB
Xaliplatin
Li Qiang
Phase 4BBB
Fluorouracilum
Li Qiang
Phase 4BBB
Theprubicin
RWTH Aachen University
Phase 4BB

View all 50 →

Same molecule, other indications

Resminostat is also rated in:

mycosis fungoidesActive
B
Indicative · Phase 2
61 / 100
View asset →
Sezary syndromeActive
B
Indicative · Phase 2
61 / 100
View asset →
primary cutaneous T-cell non-Hodgkin lymphomaActive
B
Indicative · Phase 2
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →